Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vernalis has signed a drug discovery collaboration with Genentech, a member of the Roche Group.
Subscribe to our email newsletter
Genentech will make use of Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target.
Vernalis CEO Ian Garland said the company is happy that Genentech chose them to work on the concerned target.
"Their selection of Vernalis further endorses our market leading fragment and structure-based drug discovery platform and validates our strategy to substantially fund our research activities through collaborations," Garland added.
The financial terms of this collaboration have not been revealed.